David M. Hyman

Abstract CT118: Efficient basket trial designs

Kristen M. Cunanan, Alexia Iasonos, Ronglai Shen, 2016 .

DENSE MEDIA CYCLONE OPTIMIZATION

David M. Hyman, 2002 .

A view on drug resistance in cancer

Neil Vasan, David M. Hyman, J. Baselga, 2019, Nature.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

David M. Hyman, Vivek Subbiah, Jordi Rodon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms

Ahmet Dogan, Omar Abdel-Wahab, Alexia Iasonos, 2019, Nature.

Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.

David M. Hyman, Vivek Subbiah, Jean-Yves Blay, 2017 .

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David M. Hyman, David S. Hong, Alberto S. Pappo, 2017 .